- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ACADIA Pharmaceuticals Inc (ACAD)
"ACADIA Pharmaceuticals Inc stock price live, this page displays NASDAQ ACAD stock exchange data. View the ACAD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the ACADIA Pharmaceuticals Inc real time stock price chart below.
What Is the ACADIA Pharmaceuticals Inc Stock Price Today?
The ACADIA Pharmaceuticals Inc stock price today is 17.57.
What Is the Stock Symbol for ACADIA Pharmaceuticals Inc?
The stock symbol for ACADIA Pharmaceuticals Inc is ""ACAD.""
What Stock Exchange Does ACADIA Pharmaceuticals Inc Trade On?
ACADIA Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is ACADIA Pharmaceuticals Inc a Good Stock to Buy?
Determining whether ACADIA Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACAD quote. (ISIN: US0042251084)"
What Is the ACADIA Pharmaceuticals Inc Stock Price Today?
The ACADIA Pharmaceuticals Inc stock price today is 17.57.
What Is the Stock Symbol for ACADIA Pharmaceuticals Inc?
The stock symbol for ACADIA Pharmaceuticals Inc is ""ACAD.""
What Stock Exchange Does ACADIA Pharmaceuticals Inc Trade On?
ACADIA Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is ACADIA Pharmaceuticals Inc a Good Stock to Buy?
Determining whether ACADIA Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACAD quote. (ISIN: US0042251084)"
17.57
+0.05(+0.29%)
Closed
After Hours
17.570.00(0.00%)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.35
17.89
52 wk Range
14.15
29.29
ACAD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
17.3517.89
52 wk Range
14.1529.29
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ACAD Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Strong Buy
Price Target
24.95
Upside
+41.99%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
ACADIA Pharmaceuticals Inc Company Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer’s disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals Inc SWOT Analysis
Daybue's Dilemma | Explore ACADIA's strategy to overcome Daybue's slower-than-expected market uptake, with only 30% of diagnosed Rett syndrome patients initiating therapy |
NUPLAZID's Strength | Discover how NUPLAZID's robust performance is offsetting Daybue's challenges, providing stable cash flow and supporting ACADIA's financial position |
Pipeline Potential | Delve into ACADIA's promising pipeline, including ACP-101 for Prader-Willi Syndrome and ACP-204 for Alzheimer's Disease Psychosis, with peak revenue estimates |
Market Outlook | Analysts project ACADIA's revenues to reach $1,112 million by 2025, with an average price target of $32.43, reflecting varied views on growth potential |
ACADIA Pharmaceuticals Inc Earnings Call Summary for Q2/2024
- Q2 2024: $242M revenue from NUPLAZID and DAYBUE; $500M+ cash reserves; no debt
- NUPLAZID: 11% net sales increase; raised annual guidance. DAYBUE: 11% sales growth, slower new patient starts
- Focus on Parkinson's disease awareness; direct-to-consumer campaigns planned for 2025-2026
- Advancing Phase 3 studies for Prader-Willi syndrome and Alzheimer's disease psychosis
- Expects sustainable cash flow; targeting physicians beyond centers of excellence for market share growth
Last Updated: 08/07/2024, 11:08 PM
Read Full TranscriptCompare ACAD to Peers and Sector
Metrics to compare | ACAD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACADPeersSector | |
|---|---|---|---|---|
P/E Ratio | 22.7x | −1.0x | −0.6x | |
PEG Ratio | 0.12 | 0.00 | 0.00 | |
Price/Book | 5.1x | 0.5x | 2.6x | |
Price / LTM Sales | 3.1x | 2.4x | 3.1x | |
Upside (Analyst Target) | 48.0% | 367.3% | 53.0% | |
Fair Value Upside | Unlock | 22.8% | 8.0% | Unlock |
Analyst Ratings
12 Buy
6 Hold
1 Sell
Ratings:
19 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 24.95
(+41.99% Upside)
Earnings
Latest Release
Nov 06, 2024
EPS / Forecast
0.20 / 0.14
Revenue / Forecast
250.40M / 248.60M
People Also Watch
FAQ
What Is the ACADIA (ACAD) Stock Price Today?
The ACADIA stock price today is 17.57
What Stock Exchange Does ACADIA Trade On?
ACADIA is listed and trades on the NASDAQ stock exchange.
What Is the Stock Symbol for ACADIA?
The stock symbol for ACADIA is "ACAD."
What Is the ACADIA Market Cap?
As of today, ACADIA market cap is 2.92B.
What is ACADIA Earnings Per Share?
The ACADIA EPS is 0.777.
What Is the Next ACADIA Earnings Date?
ACADIA will release its next earnings report on Mar 02, 2025.
From a Technical Analysis Perspective, Is ACAD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.